Indeed, we found high levels of IFNγ secretion by both aEGFRvIII and aEGFRvIII-SGRP CARs in vitro and in vivo but only SGRP-armored CARs were able to cope with a high tumor load of target-negative cells in vivo. This evidence concerns the gene IFNG and neoplasm.